FDA Adverse Event Malfunction Summary report: N

FLOW-I C30

MDR report key: 8185545 · Received December 20, 2018

Report

Report Number
8010042-2018-00692
Event Type
Malfunction
Date Received
December 20, 2018
Date of Event
November 27, 2018
Report Date
March 15, 2019
Manufacturer
MAQUET CRITICAL CARE AB
Product Code
BSZ
PMA / PMN Number
K160665
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
SW
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 0

GETINGE USA SALES, LLC (IMPORTER) IS SUBMITTING THIS REPORT ON BEHALF OF MAQUET CRITICAL CARE AB (MANUFACTURER). REF. EXEMPTION #: E2018003. GETINGE USA SALES, LLC 45 BARBOUR POND DRIVE WAYNE, NJ 07470. CONTACT PERON: (B)(4). THE ANESTHESIA WORKSTATION WAS EXAMINED BY THE HOSPITAL TECHNICIANS WITHOUT BEING ABLE TO REPRODUCE THE ISSUES. NO INFORMATION HAS BEEN PROVIDED WHETHER ANY PARTS HAVE BEEN REPLACED OR IF THE REPORTED ISSUE HAS RECURRED SINCE. DEVICE LOGS HAVE BEEN RECEIVED AND THE REPORTED ISSUE WITH A HIGH FICO2 LEVEL DESPITE HAVING CHANGED THE CO2 ABSORBER CAN BE CONFIRMED. THE CLINICAL ALARMS THAT WERE GENERATED SHOW THAT HIGH FICO2 VALUES WERE MEASURED BUT WITHOUT HAVING RECEIVED ANY ADDITIONAL INFORMATION SURROUNDING THE EVENT SUCH AS REPLACED PARTS, WE CANNOT DETERMINE THE CAUSE OF THE REPORTED INCREASED LEVEL OF FICO2 VALUES.

Additional Manufacturer Narrative · 0

GETINGE USA SALES, LLC (IMPORTER) IS SUBMITTING THIS REPORT ON BEHALF OF MAQUET CRITICAL CARE AB (MANUFACTURER). REF. EXEMPTION #: E2018003. GETINGE USA SALES, LLC 45 BARBOUR POND DRIVE WAYNE, NJ 07470. CONTACT PERSON: (B)(4).

Description of Event or Problem · 0

MANUFACTURER'S REF #: (B)(4).

Description of Event or Problem · 0

IT WAS REPORTED THAT THE ANESTHESIA WORKSTATION MEASURED A HIGHER FICO2 LEVEL THAN EXPECTED DURING AN EXTENDED TIME PERIOD. THERE WAS NO PATIENT HARM. (B)(4).

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1023497 FLOW-I C30 GAS-MACHINE, ANESTHESIA BSZ MAQUET CRITICAL CARE AB C30

Patients

Seq Age Sex Outcome Treatment
1